Keywords: Non-small cell lung cancer; EGFR mutation; Afatinib; Acquired resistance; T790M; Progression biopsy;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells
Keywords: EGFR (epidermal growth factor receptor); NSCLC (non-small cell lung cancer); Erlotinib; EGFR-Targeted therapy; De novo mutation; Erlotinib-resistance; T790M;
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
Keywords: EGFR; T790M; Osimertinib; ddPCR;
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045
Keywords: EGFR; T790M; C797S; Drug-resistance; EAI045;
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival
Keywords: Lung cancer; EGFR; T790M; Drug resistance; Osimertinib; Survival; Brain metastasis;
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
Keywords: EGFR; NSCLC; SCLC transformation; T790M; Liquid biopsy; ddPCR;
Brief Report on the Detection of the EGFR T790M Mutation in Exhaled Breath Condensate from Lung Cancer Patients
Keywords: Liquid biopsy; Biomarkers; T790M; Exhaled breath condensate; Lung cancer;
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance
Keywords: EGFR; T790M; cell-free DNA; next-generation sequencing;
Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review
Keywords: Acquired resistance; Histologic transformation; Non-small-cell lung cancer; Osimertinib; T790M;
Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation
Keywords: EGFR inhibitors; Pyrimidine derivatives; Mutant selective inhibitors; AZD9291; T790M;
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach
Keywords: Afatinib; Del19; Gefitinib; L858R; T790M;
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors
Keywords: ErbB family blocker; Non-small-cell lung cancer; Pulsatile; T790M; Tolerability;
Short communicationEmergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Keywords: EGFR; G724S; T790M; Acquired resistance; Osimertinib; Lung cancer;
Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis
Keywords: T790M; Non-small cell lung cancer; Precision medicine; Urine; Biopsy; ctDNA;
ReviewOptimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
Keywords: Acquired resistance; Epidermal growth factor receptor mutation; Non-small cell lung cancer; Osimertinib; T790M; Tyrosine kinase inhibitor;
Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
Keywords: EGFR; ZEB1; T790M; C797S; TOPK;
Original researchProgrammed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer
Keywords: Programmed death-ligand 1; T790M; Epidermal growth factor receptor mutation; Non-small cell lung cancer; Rebiopsy;
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; Acquired resistance; T790M; MET amplification; [11C]erlotinib;
Original articleCharacterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer
Keywords: EGFR TKI; E19del; L858R; T790M; L861Q;
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Keywords: NSCLC; EGFR; T790M; Liquid biopsy; Osimertinib; Rociletinib; Olmutinib;
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway
Keywords: NSCLC; non-small cell lung cancer cell; ROS; reactive oxygen species; EGFR; epidermal growth factor receptor; T790M; a substitution mutation of threonine with methionine at position 790 of EGFR; TrxR; thioredoxin reductases; MTT; 3-(4,5-dimetrylthiazol)-2
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
Keywords: CRM1; chromosome region maintenance 1; EGFR; epidermal growth factor receptor; EMT; epithelial-mesenchymal transition; LMB; leptomycin B; MTT; 3-(4,5-dimetrylthiazol)-2,5-diphenyltetrazolium bromide; NSCLC; non-small cell lung cancer; TKIs; tyrosine kinas
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Keywords: NSCLC; T790M; BRAF V600E; Acquired resistance; Targeted therapy;
Structural pharmacological studies on EGFR T790M/C797S
Keywords: EGFR; T790M; C797S; Drug-resistance; Gö6976;
Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
Keywords: Osimertinib; Biomarker; T790M; EGFR; NSCLC;
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
Keywords: Non-small cell lung cancer; Tyrosine kinase inhibitor; EGFR mutation; Osimertinib; T790M;
Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC
Keywords: Epidermal growth factor receptor; Tyrosine kinase inhibitors; Non-small cell lung cancer; T790M; Mutant-selective; GGCWHBCVZDGOED-UHFFFAOYSA-N; FTUBJFSTQHOKJF-UHFFFAOYSA-N; OMTVOJFWRBBVMU-UHFFFAOYSA-N; GWACGSDFEQNCCR-UHFFFAOYSA-N; AIANAUPKJGDVRP-UHFFFAOYS
Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer
Keywords: Lung cancer; EGFR; Mutation; T790M; Evolution
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; T790M; L858R; Exon 19 deletions; Meta-analysis
Recent progress on third generation covalent EGFR inhibitors
Keywords: EGFR; Covalent inhibitor; T790M; Oncogenic mutation; Lung cancer; NSCLC; SBDD; Drug resistance;
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines
Keywords: NSCLC; EGFR; T790M; Quinazoline; Adamantyl;
Les cancers bronchiques non à petites cellules EGFR-mutés
Keywords: Mutations EGFR; Traitements ciblés; EGFR mutation; Targeted therapies; Resistance mutations; T790M;
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
Keywords: Urine; Circulating tumor DNA; NSCLC; EGFR mutations; T790M;
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review
Keywords: Adenocarcinoma; Afatinib; Erlotinib; Exon 19; Gefitinib; L858R; Osimertinib; TKI; T790M;
EGFR T790M resistance mutation in non small-cell lung carcinoma
Keywords: EGFR; T790M; Mutation; Resistance; Non small-cell lung cancer;
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
Keywords: Epidermal growth factor receptor mutation; T790M; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired resistance; Rebiopsy
Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer
Keywords: EGFR-TKI; non-small-cell lung cancer; T790M; methylation; resistance;
Current and Future Approaches in the Management of Non–Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs
Keywords: Afatinib; EGFR; NSCLC; Oligoprogressive; T790M
V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors
Keywords: Susceptibility; Small inhibitory RNA; Crystallographic analysis; T790M; L858R; Lung adenocarcinoma;
Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
Keywords: Epidermal growth factor receptor; T790M; Tyrosine kinase inhibitor; Afatinib; Resistance;
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents
Keywords: T790M; EGFR; Non-small cell lung cancer; RNA interference; Afatinib; Cetuximab;
p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles
Keywords: Gefitinib; EGFR; T790M; Histone; p300/CBP;
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
Keywords: Marsdenia tenacissima extract; Gefitinib resistance; NSCLC; T790M; K-ras mutations;
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
Keywords: EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; EMT; epithelial-mesenchymal transition; T790M; threonine-to-methionine mutation at codon 790 of EGFR; p-MET; phosphorylation of MET; p-Akt; phosphorylation of Akt; IHC; immunohistoc
Discovery of selective irreversible inhibitors for EGFR-T790M
Keywords: EGFR; Kinase inhibitor; T790M; Mutant selective
A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA
Keywords: Lung cancer; EGFR-TKI; T790M; Plasma DNA; Monitoring system
Subsequent Chemotherapy Improves Survival Outcome in Advanced Non–Small-Cell Lung Cancer With Acquired Tyrosine Kinase Inhibitor Resistance
Keywords: Best supportive care; EGFR; Erlotinib; Gefitinib; T790M; Taxanes
Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer
Keywords: EGFR; KRAS; Mutation; T790M; Wild type
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Keywords: NSCLC; EGFR; HER; T790M; Irreversible; TKI; Antibody
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
Keywords: EGFR; NSCLC; Adenocarcinoma; Prospective study; Acquired resistance; T790M